IP Library Granted Patent US 7,816,320
Granted Patent B2
US 7,816,320 · App. 11/316,483 · Granted Oct 19, 2010

Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35

Assignee: AMBRX, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,816,320
App. No.
11/316,483
Granted
Oct 19, 2010
Kind
B2
Abstract

Formulations of modified human growth hormone polypeptides are provided.

Claims (18)

1. A pharmaceutical formulation of a human growth hormone (hGH) variant wherein said formulation comprises: a) a buffer; b) at least one carrier, excipient, or stabilizer, and; c) a pharmaceutically effective quantity of the hGH variant wherein the hGH variant comprises a non-naturally encoded amino acid at position 35 and wherein the non-naturally encoded amino acid is p-acetyl phenylalanine.

2. The formulation of claim 1 wherein the hGH is PEGylated.

3. The formulation of claim 1 , wherein the pH of the buffer is between about pH 4.0 and about pH 8.5.

4. The formulation of claim 1 , wherein the pH of the buffer is between about pH 6.0 and about pH 7.3.

5. The formulation of claim 1 , wherein the pH of the buffer is between about pH 5.5 and about 8.0.

6. The formulation of claim 1 , wherein the pharmaceutically effective quantity of hGH is between about 2mg/mL and about 50 mg/mL.

7. The formulation of claim 1 , wherein the buffer is between about pH 5.0 and about pH 7.5.

8. The formulation of claim 1 , wherein the buffer is histidine.

9. The formulation of claim 8 , wherein the histidine is at a concentration of about 0.1 mM to about 200 mM.

10. The formulation of claim 9 , wherein the histidine is at a concentration of about 1 mM to about 75 mM.

11. The formulation of claim 10 , wherein the histidine is at a concentration of about 5 mM to about 30 mM.

12. The formulation of claim 1 , wherein the formulation further comprises d) a surfactant.

13. The formulation of claim 12 , wherein the surfactant is a non-ionic surfactant.

14. The formulation of claim 13 , wherein the non-ionic surfactant is at about 0.0001% to about 10%.

15. The formulation of claim 13 , wherein the non-ionic surfactant is at about 0.01% to about 10%.

16. The formulation of claim 13 , wherein the non-ionic surfactant is at about 0.1% to about 5%.

17. The formulation of claim 13 , wherein the non-ionic surfactant is at about 0.1% to about 1%.

18. The formulation of claim 13 , wherein the non-ionic surfactant is at about 0.0001% to about 1%.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2006
From: HAYS, ANNA-MARIA; BUECHLER, YING; LITZINGER, DAVID C.
To: AMBRX, INC.
Reel/Frame 017577/0323 →
Continuity (4)
Provisional Application 6063861600 · Dec 22, 2004
Provisional Application 6068061700 · May 13, 2005
Provisional Application 6072803500 · Oct 17, 2005
Related Publication 20060135427A1 · Jun 22, 2006